


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A compound represented by the formula



wherein Ring A represents ~~an optionally substituted~~ a pyridine ring which may have one or two C₁₋₄ alkyl groups, X represents ~~an electron-attracting~~ a nitrile group, Y represents ~~-CH=CH-~~ or ~~-(CH₂)₂-~~ ~~(CH₂)₂~~, R¹ represents (1) a C₅₋₇ cycloalkyl group optionally fused with a benzene ring, (2) a C₇₋₁₉ aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or (4) a C₆₋₁₄ aryloxy-C₁₋₄ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and a C₁₋₄ alkoxy group, and one of R² and R³ each independently represent is a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₄ aryl and C₇₋₁₉ aralkyl or an optionally substituted heterocyclic group selected from the group consisting of tetrahydropyranyl, pyranyl and pyridyl or a C₁₋₄ alkyl group, and the other is a C₆₋₁₄ aryl group, a C₇₋₁₉ aralkyl group, a C₃₋₁₀ cycloalkyl group, a tetrahydropyranyl group, a pyranyl group or a pyridyl group or a C₁₋₆ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri- halogeno-C₁₋₄

alkyl group, a C₁₋₄ alkoxy group, a C₁₋₄ alkoxy-carbonyl group, a cyano group, a C₁₋₄ alkyl-carbonylamino group and a hydroxyl group or a salt thereof.

2. (Canceled).

3. (Canceled).

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. **(Original)** (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. (Canceled).
9. (Currently amended) A ~~medicine~~vanilloid receptor agonist comprising the compound according to claim 1.
10. (Canceled).
11. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~9 which is for local administration.
12. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~9 which is an agent for treating overactive bladder.
13. (Currently amended) The vanilloid receptor agonist according to claim ~~10~~9 which is an analgesic.
14. (Previously presented) A method of treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1.
15. (Previously presented) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1.

16. (Canceled).

17. (Canceled).